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Background: High-density lipoprotein (HDL) has been shown to confer cardiovascular protection in clinical and
epidemiologic studies. Emerging evidence suggests that many of the cardioprotective functions of HDL may be
due to the phospholipid sphingosine-1-phosphate (S1P).
Presentation of the hypothesis: HDL-S1P binds to S1P receptors in the heart, activating PI3K/Akt signaling and
myocyte survival. PI3K/Akt is a classic signaling modulator of autophagy. Excessive autophagy due to cell death and
cardiomyocyte loss may contribute to impaired heart function during pressure overload-induced heart failure.
Therefore, we hypothesize that HDL-S1P may suppress excessive autophagy of cardiomyocytes through activation
of PI3K/Akt signaling. Further, reconstituted HDL (including S1P) may protect heart function during pressure
overload-induced heart failure.
Testing the hypothesis: We will design the following experiments to test this hypothesis. (1) We will treat cells
and mice with PI-3 kinase inhibitors to examine if HDL-S1P downregulates expression of Autophagy-related genes
(ATGs) and proteins via activation of PI3K/Akt signaling. (2) We will use siRNA against S1P receptors or inhibitors of
S1P receptors to determine which types of S1P receptors participate in this mechanism. (3) We will also examine
if reconstituted HDL (including S1P) improves heart function during pressure overload-induced heart failure by
suppressing excessive autophagy of cardiomyocytes through activation of PI3K/Akt signaling.
Implications of the hypothesis: Understanding the autophagy signaling pathway modulated by HDL-S1P
will make a major contribution to the field by identifying a novel mechanism for cardiovascular protection of
high-density lipoprotein. Further, using reconstituted HDL to improve heart function would provide a novel
therapeutic approach for pressure overload–induced heart failure.
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Despite considerable improvements in medical care over
the past several decades, atherosclerotic cardiovascular
diseases, including coronary heart disease (CHD) and
stroke, remain a major public health challenge. In fact,
atherosclerotic cardiovascular diseases are responsible
for nearly 50% of all deaths and are the main cause of
disease burden. Post-hoc analyses of prospective trials in* Correspondence: yeping301@sina.com
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reveal that elevated plasma triglyceride levels and low
plasma concentrations of high-density lipoprotein choles-
terol (HDL-C) are intimately associated with high cardio-
vascular risk; this risk was observed even at or below the
recommended low-density lipoprotein cholesterol levels
[1,2]. Furthermore, HDL-C concentrations and cardiovas-
cular risk have been shown to have an inverse relationship
in clinical and epidemiologic studies.
Cardiovascular protection of HDL has been explored.
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over, there is clear evidence that HDL particles exert
pleiotropic effects on anti-inflammatory, anti-oxidative,
anti-apoptotic, and vasodilatory properties [3-5]. Apo
A-I is a major apolipoprotein of HDL and functions
as an important bioactive cardioprotective component
[6]. Emerging evidence suggests that many of the car-
dioprotective functions of HDL, such as vasodilation,
angiogenesis and endothelial barrier function, protection
against ischemia/reperfusion injury, and inhibition of ath-
erosclerosis, may be due to the phospholipid sphingosine-
1-phosphate (S1P) [7,8]. HDL-bound S1P (HDL-S1P)
plays a role in HDL cardiac protection and represents a
potential target for therapeutic interventions.
Presentation of the hypothesis
Direct effects of HDL-S1P on the heart
S1P is a bioactive lysophospholipid that regulates many
important cellular processes. The major source of plasma
S1P is from blood cells (mainly erythrocytes, platelets, and
leukocytes) [9,10]. Most circulating S1P is not free;
instead, it is bound to plasma proteins, which seem to
“buffer” S1P. The majority (50–70%) of total plasma S1P
is transported by HDL, especially HDL3 particles [11], and
approximately 30% of total plasma S1P is transported by
albumin. Several studies suggest differences in the func-
tions of HDL-linked S1P and albumin-linked S1P; S1P
in the former form has been proposed to exert anti-
atherosclerotic functions [12]. The percentage of S1P
transported in plasma lipoproteins may be positively
correlated with HDL-C concentrations. This suggests
that individuals with high HDL-C levels may have high
HDL-S1P levels, which further supports the role of S1P
as a mediator of the protective effects of HDL against
atherogenesis [13]. Furthermore, Theilmeier et al. sug-
gested that HDL and S1P may attenuate the infarction
size of an in-vivo mouse model of myocardial ischemia/
reperfusion by inhibiting inflammatory neutrophil re-
cruitment and cardiomyocyte apoptosis in the infarcted
area [14].
In addition to the indirect cardioprotective effects of
HDL, experimental myocardial infarction studies indicate
that HDL also exerts direct cardioprotection mediated by
S1P. The first report to attribute the direct cardioprotective
effects of HDL on S1P showed that HDL protected
mouse cardiomyocytes from hypoxia-reoxygenation
through HDL-S1P [15]. Many S1P actions are mediated
through subtypes of S1P G-protein-coupled receptors,
which comprise S1P1–5. S1P binding to S1P1, 2, or 3
receptors in the heart activates downstream signaling
pathways that promote myocyte survival [16]. FTY720
(Fingolimod), a S1P1,3–5-R pan-agonist, was recently
approved by the FDA in 2010 as the first orally active
drug for the treatment of relapsing-remitting MS.FTY-720 is able to prevent the initiation of cardiac
hypertrophy. FTY-720 profoundly reverses existing
hypertrophy/fibrosis through negative regulation of NFAT
activity in cardiomyocytes through Gi signaling and reduc-
tion of periostin expression in the extracellular matrix,
which renders a favourable milieu for myocytes, leading to
improved cardiac performance. Tao R et al. reported that
myocyte survival is abrogated by the PI-3 kinase inhibitor
wortmannin. The PI3K/Akt signaling pathway is activated
by S1P-associated HDL via the S1P3 receptor [17]. Fur-
thermore, in neonatal rat ventricular myocytes, native and
reconstituted HDL were protective against doxorubicin-
induced apoptosis due to the S1P component of HDL
[18]; the cardioprotection was mediated by the S1P2
receptor, ERK1/2, and STAT3.
Autophagy and pressure-loading heart failure
In contrast to cell survival, there are three types of cell
death: necrosis, apoptosis, and autophagy.
Autophagy is a housekeeping mechanism that removes
aberrant and dysfunctional molecules and organelles
from cells. It is a catabolic trafficking pathway for bulk
destruction and turnover of long-lived proteins and organ-
elles via regulated lysosomal degradation. Autophagy-
related genes (ATGs) control the process of autophagy.
Beclin-1 (Atg6) is needed for vesicle nucleation of autop-
hagosomes. Vesicle elongation requires two conjugation
pathways. One of these involves microtubule-associated
protein 1 light chain 3 (LC3 or Atg8), which is converted
from its soluble form into a vesicle-associated form during
the process of elongation. The elongation of the isolation
membrane is followed by maturation of the autophago-
some, which fuses with a lysosome, thereby generating an
autophagolysosome or autolysosome. Class I PI3K/Akt
is the classic signaling pathway to regulate expression
of ATGs; activation of PI3K/Akt increases expression
of ATGs.
In the heart, autophagy occurs constitutively at low
basal levels to perform housekeeping functions that
maintain cardiac function and morphology [19]. However,
autophagic processes in cardiomyocytes are up-regulated
in response to altered internal needs and environmental
stressors, such as removal of protein aggregates, ATP
depletion (e.g., during starvation), and oxidative damage
(e.g., via reactive oxygen species) [20,21]. These observa-
tions strongly suggest that autophagy is a survival mech-
anism. Indeed, it has been demonstrated that autophagy
plays a critical role in the maintenance of ventricular
function during starvation in the adult [22]. On the other
hand, the occurrence of autophagic structures in dying
cells of different organisms has led to the hypothesis that
autophagy may also play a causative role in stress-induced
cell death [23]. It has become clear that failing hearts
simultaneously exhibit apoptosis, necrosis, and autophagy
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failing human heart; upregulation of this process has also
been reported in animal models of pressure overload-
induced heart failure [25]. The extent of autophagic flux
can increase to maladaptive levels during load-induced
heart failure. Excessive autophagy leads to autophagic cell
death and loss of cardiomyocytes, which may contribute
to heart failure [26]. Autophagy functions predominantly
as a pro-survival mechanism during nutrient deprivation
or other forms of cellular stress. However, when autoph-
agy is strongly induced, the autophagic machinery may
also be used for self-destruction. Hence, when autophagic
cell death occurs in cardiac cells, it may contribute to the
progress of heart failure.
Hypotheses
HDL-S1P binds to S1P receptors in the heart, activating
PI3K/Akt signaling and subsequent myocyte survival.
PI3K/Akt is a classic signaling modulator of autophagy.
Excessive autophagy due to cell death and loss of cardio-
myocytes may impair heart function during pressure
overload-induced heart failure. Our preliminary results
indicated that reconstituted HDL (including S1P) sup-
pressed autophagy of rat cardiomyocytes in the presence
of phenylephrine at serum-deprivation (unpublished
observations). Therefore, we hypothesize that HDL-S1P
suppresses excessive cardiomyocyte autophagy by activat-
ing PI3K/Akt signaling. Further, we propose that reconsti-
tuted HDL (including S1P) protects heart function during
pressure overload-induced heart failure.
Testing the hypothesis
We will design the following experiments to test this hy-
pothesis. (1) We will treat neonatal rat cardiomyocytes
and mice with PI-3 kinase inhibitors to examine if
HDL-S1P downregulates expression of Autophagy-related
genes (ATGs) and proteins via activation of PI3K/Akt
signaling. (2) We will use siRNA against S1P receptors
or inhibitors of S1P receptors to determine which types
of S1P receptors participate in this mechanism. (3) We
will also examine if reconstituted HDL (including S1P)
improves heart function during pressure overload–in-
duced heart failure by suppressing excessive autophagy of
cardiomyocytes through activation of PI3K/Akt signaling.
Implications of the hypothesis
Understanding the autophagy signaling pathway mod-
ulated by HDL-S1P will make a major contribution to
the field by identifying a novel mechanism for cardiovas-
cular protection of high-density lipoprotein. Further, using
reconstituted HDL (including S1P) to improve heart func-
tion would provide a novel therapeutic approach for pres-
sure overload–induced heart failure.Abbreviations
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